Literature DB >> 17914114

Gastrointestinal stromal tumors regularly express synaptic vesicle proteins: evidence of a neuroendocrine phenotype.

Per Bümming1, Ola Nilsson, Håkan Ahlman, Anna Welbencer, Mattias K Andersson, Katarina Sjölund, Bengt Nilsson.   

Abstract

Gastrointestinal stromal tumors (GISTs) are thought to originate from the interstitial cells of Cajal, which share many properties with neurons of the gastrointestinal tract. Recently, we demonstrated expression of the hormone ghrelin in GIST. The aim of the present study was therefore to evaluate a possible neuroendocrine phenotype of GIST. Specimens from 41 GISTs were examined for the expression of 12 different synaptic vesicle proteins. Expression of synaptic-like microvesicle proteins, e.g., Synaptic vesicle protein 2 (SV2), synaptobrevin, synapsin 1, and amphiphysin was demonstrated in a majority of GISTs by immunohistochemistry, western blotting, and quantitative reversetranscriptase PCR. One-third of the tumors also expressed the large dense core vesicle protein vesicular monoamine transporter 1. Presence of microvesicles and dense core vesicles in GIST was confirmed by electron microscopy. The expression of synaptic-like microvesicle proteins in GIST was not related to risk profile or to KIT/platelet derived growth factor alpha (PDGFRA) mutational status. Thus, GISTs regularly express a subset of synaptic-like microvesicle proteins necessary for the regulated secretion of neurotransmitters and hormones. Expression of synaptic-like micro-vesicle proteins, ghrelin and peptide hormone receptors in GIST indicate a neuroendocrine phenotype and suggest novel possibilities to treat therapy-resistant GIST.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17914114     DOI: 10.1677/ERC-06-0014

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  16 in total

1.  KIT and PDGFRA in esophageal pure small cell carcinoma.

Authors:  Tadashi Terada
Journal:  Int J Clin Exp Pathol       Date:  2011-10-16

2.  Neuroendocrine carcinoma of the esophagus: a case report with immunohistochemical and molecular genetic analyses of KIT and PDGFRA.

Authors:  Tadashi Terada
Journal:  Med Oncol       Date:  2010-03-31       Impact factor: 3.064

3.  Expression of NCAM (CD56), chromogranin A, synaptophysin, c-KIT (CD117) and PDGFRA in normal non-neoplastic skin and basal cell carcinoma: an immunohistochemical study of 66 consecutive cases.

Authors:  Tadashi Terada
Journal:  Med Oncol       Date:  2013-01-05       Impact factor: 3.064

4.  Successful imatinib therapy for neuroendocrine carcinoma with activating Kit mutation: a case study.

Authors:  James Perkins; Patrick Boland; Steven J Cohen; Anthony J Olszanski; Yan Zhou; Paul Engstrom; Igor Astsaturov
Journal:  J Natl Compr Canc Netw       Date:  2014-06       Impact factor: 11.908

5.  Small cell neuroendocrine carcinoma of the esophagus: report of 6 cases with immunohistochemical and molecular genetic analysis of KIT and PDGFRA.

Authors:  Tadashi Terada
Journal:  Int J Clin Exp Pathol       Date:  2013-02-15

6.  Primary small cell carcinoma of the stomach: a case report with an immunohistochemical and molecular genetic analysis.

Authors:  Tadashi Terada
Journal:  Int J Clin Exp Pathol       Date:  2013-02-15

Review 7.  Duodenal somatostatinoma presenting as obstructive jaundice with the coexistence of a gastrointestinal stromal tumour in neurofibromatosis type 1: a case with review of the literature.

Authors:  Subhanudh Thavaraputta; Suzanne Graham; Ana M Rivas Mejia; Joaquin Lado-Abeal
Journal:  BMJ Case Rep       Date:  2019-01-10

8.  Evidence for Ca(2+)-regulated ATP release in gastrointestinal stromal tumors.

Authors:  Erik Berglund; David Berglund; Pinar Akcakaya; Mehran Ghaderi; Elisabetta Daré; Per-Olof Berggren; Martin Köhler; Craig A Aspinwall; Weng-Onn Lui; Jan Zedenius; Catharina Larsson; Robert Bränström
Journal:  Exp Cell Res       Date:  2013-03-13       Impact factor: 3.905

9.  SLITRK3 expression correlation to gastrointestinal stromal tumor risk rating and prognosis.

Authors:  Chao-Jie Wang; Zi-Zhen Zhang; Jia Xu; Ming Wang; Wen-Yi Zhao; Lin Tu; Chun Zhuang; Qiang Liu; Yan-Yin Shen; Hui Cao; Zhi-Gang Zhang
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

10.  Botulinum neurotoxin type A inhibits synaptic vesicle 2 expression in breast cancer cell lines.

Authors:  C Bandala; A L Cortés-Algara; C M Mejía-Barradas; I Ilizaliturri-Flores; R Dominguez-Rubio; C I Bazán-Méndez; E Floriano-Sánchez; J P Luna-Arias; M Anaya-Ruiz; E Lara-Padilla
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.